Company intelligence / Profile preview

Parker Hughes Institute

Roseville, Minnesota, United States

Ownership: Private
Development stage: Other

Overview

Historically, the institute advanced several novel small molecule inhibitors and immunotoxins into early-phase clinical trials. Most notable was the B43-PAP immunotoxin which showed activity in relapsed B-lineage acute lymphoblastic leukemia (ALL). Development of many programs ceased when the institute closed in the mid-2000s.

Therapeutic areas: Oncology
Modalities: Small moleculeFusion toxin protein therapyAntibody-drug conjugateMonoclonal antibody
Industry: Academic Hospital/University/Research

Partnerships

National Cancer Institute (NCI)

Beyond the preview

Go deeper on Parker Hughes Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parker Hughes Institute.

Explore the full profile